Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
RECENT ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Its growth cooling, can Kanzhun stay employed in a slowing economy?
2076.HK BZ.US
-
Blue Moon shadowed by aggressive promotional spending in slowing economy
6993.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
BRIEF: Bossini privatization approved, to delist in mid-March
0592.HK 0933.HK 2331.HK
-
Yan Palace flies back to profit growth as revenue sags
1497.HK
